September 2025 in “Medicine & Science in Sports & Exercise” In this rodent study, the researchers found that different hormone therapies affected gut microbiota and goblet cell counts, with notable microbial shifts observed between groups receiving estrogen with and without an orchiectomy, linked to estrogen metabolism.
3 citations
,
May 2020 in “Journal of Cellular and Molecular Medicine” This study identified critical roles for the gene GREM1 in the differentiation and expansion of endothelial progenitors derived from human urinary induced pluripotent stem cells.
47 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This review examines the pathogenesis of premature hair graying and potential treatment avenues, but reports no new experimental outcomes, highlighting ongoing research challenges and hopes for drug development.
2 citations
,
January 2022 in “The Application of Clinical Genetics” This case report presents the first Russian patient with Meier-Gorlin syndrome 5, expanding clinical understanding through the identification of two novel CDC6 gene variants.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.
32 citations
,
August 2003 in “Journal of the European Academy of Dermatology and Venereology” This article reviews the clinical aspects and potential mechanisms of chronic graft vs host disease skin manifestations, describing a novel form of premature skin aging, but presents no new research findings.
6 citations
,
January 2019 in “Indian Journal of Pharmacology” In this case study, a 14-year-old female with premature hair graying showed improved hair color after treatment with a topical Melitane 5% formulation and oral hair supplements.
May 2024 in “Rossijskaâ oftalʹmologiâ onlajn” In this case report, a 17-year-old Korean female with Vogt–Koyanagi–Harada syndrome showed positive improvement in her symptoms following systemic glucocorticosteroid pulse therapy, highlighting the rarity and importance of early disease detection.
1 citations
,
August 2022 in “Frontiers in Medicine” This study concluded that ALRV5XR treatment significantly increased terminal hair density in both men and women with androgenetic alopecia and telogen effluvium, with more pronounced effects in women.
2 citations
,
June 2024 in “Archives of Dermatological Research” In this study, researchers compared three treatments for stable vitiligo and found that a combination of follicular cell suspension and mini punch grafting resulted in significantly better re-pigmentation after six months compared to using either method alone.
December 2025 in “Dermatology Reports” This source describes vitiligo as a chronic condition marked by the loss of skin pigmentation and discusses leukotrichia, a feature affecting 10% to 60% of cases, which arises from melanocyte loss in hair follicles and appears as well-defined white patches on the skin.
2 citations
,
January 2023 in “International journal of biological sciences” This review discusses the mechanisms of hair repigmentation and reports no clinical results; the authors suggest further research into topical treatments for reversing gray hair.
6 citations
,
June 2021 in “EClinicalMedicine” In this study, ALRV5XR significantly increased hair regrowth in women with androgenetic alopecia or telogen effluvium, with no adverse events reported.
This study presents the G4 transgenic mouse model, which suggests a direct link between polycystic ovary syndrome and the Gm10800 gene, offering a valuable tool for understanding the disease and testing treatments.
17 citations
,
April 2011 in “Journal of Dermatological Science” This study reports that the transgenic expression of Dsg1 in mice rescued the severe B6-Dsg3−/− phenotype and created a syngeneic mouse model of pemphigus vulgaris, which may aid in understanding autoimmunity mechanisms.
2 citations
,
August 2024 in “Indian Dermatology Online Journal” Premature graying of hair is mainly caused by genetics, stress, and environment, with potential treatments being explored.
The study reported that vismodegib showed significant effectiveness in treating basal cell carcinoma, particularly in patients with Gorlin-Goltz syndrome or locally advanced BCC, but also highlighted substantial side effects, requiring careful management to prevent treatment resistance and maintain remission.
This study found a significant association between premature greying of hair and deficiencies in vitamin D, vitamin B12, hypothyroidism, and disrupted iron profiles, alongside lifestyle factors like stress and smoking.
7 citations
,
July 2020 in “Pigment cell & melanoma research” In this study, RT1640 was found to promote hair pigment system regeneration and expand melanocyte stem cell pools in a mouse model, suggesting potential applications for aging-related hair disorders.
17 citations
,
February 2020 in “Journal of Pediatric and Adolescent Gynecology” This review discusses medical interventions that reproductive health experts can provide to transgender and gender diverse youth and reports no new clinical results.
January 2008 in “US endocrinology” This paper describes the hGRα gene structure and its expression, focusing on the functional properties of the longest GRα isoform, but reports no new results.
October 2025 in “Indian Journal of Dermatology Venereology and Leprology” This source suggests that the metaverse could play a crucial role in dermatology by offering new ways to manage chronic skin conditions and improve patient support and education, especially for those hesitant to seek in-person consultations.
2 citations
,
January 2017 in “Journal of Pigmentary Disorders” This study explores the complex and not yet fully understood causes of premature hair greying, noting genetic factors such as Pax3 and MITE genes, potential defects in melanin transfer, and associations with certain syndromes, while stating that effective treatments are currently lacking.
September 2023 in “Journal of The American Academy of Dermatology” This article discusses the incidence of androgenetic alopecia in transgender and gender diverse patients undergoing gender affirming hormone therapy but presents no new clinical findings, highlighting a gap in large-scale studies.
November 2025 in “Indian Journal of Nephrology” In this case study, a 43-year-old male with anti-GBM disease experienced a relapse triggered by hair dye, leading to diffuse alveolar hemorrhage; managing this with plasmapheresis, intravenous immunoglobulins, and rituximab suggests rituximab may be beneficial for relapsing cases.
2 citations
,
January 2019 in “Springer eBooks” This review discusses segmental vitiligo as part of the vitiligo clinical spectrum and highlights its role as a model for studying repigmentation, but reports no new clinical results.
August 2026 in “European Journal of Endocrinology” This study found that individualized GAHT regimens, including microdosing, effectively improved gender congruence and quality of life for non-binary individuals, but some experienced a decrease in bone mineral density.
1 citations
,
July 2025 in “BMC Psychology” This study found that gaze duration in a social evaluation task was linked to mental health outcomes in trans men, trans women, and cisgender women more than six months later.
86 citations
,
May 2013 in “American journal of obstetrics and gynecology” This article reviews the care of transgender patients, encompassing diagnosis, treatment options, and challenges in health care access, but does not present new research findings; the authors emphasize the critical role of providers in addressing transgender health needs.
July 2025 in “Journal of Medical Science And clinical Research” In this case report, a 21-year-old male was observed to have primary essential cutis verticis gyrata, a condition characterized by the excessive formation of scalp folds resembling cerebral gyri, without any additional comorbidities.